I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide) combined with daratumumab and dexamethasone to treat multiple myeloma in adults who have had at least one prior line of therapy. The approval is based on MRD-negative complete response rates, with continued approval contingent upon confirmatory progression-free survival results from an ongoing study.
- Bristol Myers Squibb won FDA accelerated approval for ZENBEXUS (iberdomide) with daratumumab and dexamethasone in multiple myeloma. * Cleared for adults with at least one prior line including a proteasome inhibitor and an immunomodulatory agent. * Decision based on MRD-negative complete response; continued approval hinges on confirmatory progression-free survival results in an ongoing cohort. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260924614211) on September 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)